Back to top
more

BioTechne Corp (TECH)

(Real Time Quote from BATS)

$54.72 USD

54.72
622,336

-0.16 (-0.29%)

Updated Aug 5, 2025 12:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Urmimala Biswas headshot

Can These 5 MedTech Stocks Hit Earnings Targets This Season?

by Urmimala Biswas

Here is a sneak peek into how five MedTech stocks, BSX, HOLX, TECH, STE and ALGN, are expected to fare in their quarterly results, slated to be released tomorrow.

Zacks Equity Research

TECH Gears Up to Report Q2 Earnings: Here's What to Expect

by Zacks Equity Research

In the second quarter, Bio-Techne is expected to have witnessed the stabilization of large-pharma customers and an increase in biotech customers' ordering trends.

Zacks Equity Research

EXEL vs. TECH: Which Stock Is the Better Value Option?

by Zacks Equity Research

EXEL vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

TECH Stock Might Rise From the Expansion of Designer Protein Portfolio

by Zacks Equity Research

Bio-Techne launches AI-engineered designer proteins to advance cell therapy and regenerative medicine.

Zacks Equity Research

BMRN or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BMRN vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

Bio-Techne Inks New Agreement With Waters Corporation: Stock to Gain?

by Zacks Equity Research

TECH enters a co-marketing and co-promotion agreement with Waters Corporation to expand the reach of advanced biotherapeutic characterization and development processes.

Zacks Equity Research

Bio-Techne Launches ESR1 Mutation Monitoring Assay: Stock to Gain?

by Zacks Equity Research

TECH's Asuragen brand unveils a highly sensitive ESR1 mutation monitoring assay.

Zacks Equity Research

Why Is Apellis Pharmaceuticals (APLS) Up 18.4% Since Last Earnings Report?

by Zacks Equity Research

Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Should You Continue to Retain Bio-Techne Stock in Your Portfolio?

by Zacks Equity Research

Bio-Techne's success with four growth verticals and expansion through acquisitions bode well.

Zacks Equity Research

Techne (TECH) Up 2.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Bio-Techne Tops Q1 Earnings & Revenue Estimates, Stock Up in Premarket

by Zacks Equity Research

TECH registers continued momentum across its Diagnostics & Spatial Biology segment.

Zacks Equity Research

Techne (TECH) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of 10.53% and 3.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

What to Expect From These 3 MedTech Stocks This Earnings Season

by Urmimala Biswas

Here is a sneak peek into how three MedTech companies, ZBH, BIO and TECH, are expected to fare in their upcoming quarterly results, slated to be released tomorrow.

Zacks Equity Research

Bio-Techne Gears Up for Q1 Earnings Release: What's in the Cards?

by Zacks Equity Research

Within Spatial Biology, TECH is expected to have recorded strong growth, banking on the strong adoption of its new spatial biology instrument COMET.

Zacks Equity Research

ACAD or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ACAD vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

New Strong Sell Stocks for August 30th

by Zacks Equity Research

AMKR, TECH and CIADY have been added to the Zacks Rank #5 (Strong Sell) List on August 30, 2024.

Zacks Equity Research

New Strong Sell Stocks for August 28th

by Zacks Equity Research

TECH, AMFPF and B have been added to the Zacks Rank #5 (Strong Sell) List on August 28, 2024.

Zacks Equity Research

New Strong Sell Stocks for August 23rd

by Zacks Equity Research

ARCO, BMTX and TECH have been added to the Zacks Rank #5 (Strong Sell) List on August 23, 2024.

Zacks Equity Research

Techne (TECH) Misses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of -3.92% and 0.65%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ultragenyx (RARE) delivered earnings and revenue surprises of 7.32% and 19.13%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Arvinas (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

GMAB or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GMAB vs. TECH: Which Stock Is the Better Value Option?

Zacks Equity Research

GMAB vs. TECH: Which Stock Is the Better Value Option?

by Zacks Equity Research

GMAB vs. TECH: Which Stock Is the Better Value Option?

Sweta Killa headshot

5 Stocks at the Forefront of S&P 500 ETF's Latest Rally

by Sweta Killa

The S&P 500 is up for the fourth consecutive session. While many stocks have powered the ETF, we have highlighted five that have led the way higher.

Zacks Equity Research

HRMY or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HRMY vs. TECH: Which Stock Is the Better Value Option?